Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Nonmetastatic, castration-resistant prostate cancer (NM-CRPC) |
Dose: Tablet – 240 mg (ie, four 60-mg tablets) Frequency: once daily |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Tablet – No approved pediatric dosage available Note: Not recommended |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment Mild-to-moderate (estimated Glomerular Filtration Rate 30-89 mL/min/1.73 m2) |
Dose: Not specified Note: No clinical significant difference in pharmacokinetics |
|
Condition: Renal impairment Severe (estimated Glomerular Filtration Rate less than 30 mL/min/1.73 m2) |
Dose: Not specified Note: Pharmacokinetics unknown |
Administration
- Take with or without food
- Same time daily
Side Effect
- All Grades Hypercholesterolemia
- nonfasting (76%)
- Anemia (70%)
- Hyperglycemia (70%)
- Hypertriglyceridemia, nonfasting (67%)
- Leukopenia (47%)
- Lymphopenia (41%)
- Fatigue (39%)
- Hyperkalemia (32%)
- Hypertension (25%)
- Rash (24%)
- Diarrhea (20%)
- Nausea (18%)
- Arthralgia (16%)
- Fall (16%)
- Weight decreased (16%)
- Hot flush (14%)
- Fracture (12%)
- Decreased appetite (12%)
- Peripheral edema (11%)
- Hypertension (14%)
- Hypothyroidism (8%)
- Pruritus (6.2%)
- Ischemic heart disease (3.7%)
- Heart failure (2.2%)
- Rash (5%)
- Fracture (3%)
- Fall (2%)
- Hypertriglyceridemia, nonfasting (2%)
- Lymphopenia (2%)
- Hyperkalemia (2%)
- Hyperglycemia (2%)
- Fatigue (1%)
- Weight decreased (1%)
- Diarrhea (1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Strong CYP2C8 or CYP3A4 inhibitors
|
Predicted to increase the steady-state exposure of active apalutamide moieties
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.